Pharmaceutical compositions for treating or preventing bone conditions
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
C07K-014/51
A61K-035/32
A61K-038/17
A61L-027/22
출원번호
US-0897397
(2010-10-04)
등록번호
US-9511115
(2016-12-06)
발명자
/ 주소
Soo, Chia
Ting, Kang
Kuroda, Shunichi
Wu, Ben
출원인 / 주소
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
대리인 / 주소
Duane Morris LLP
인용정보
피인용 횟수 :
0인용 특허 :
18
초록
Provided herein is a pharmaceutical composition for treating, preventing or ameliorating a bone or cartilage condition and methods of making and using the same.
대표청구항▼
1. A pharmaceutical composition for treating, preventing, or ameliorating a bone related condition in a mammal, comprising an effective amount of a NELL peptide and a carrier or scaffold that includes BMP2 and hyaluronan, wherein the effective amount is effective for a bone related condition selecte
1. A pharmaceutical composition for treating, preventing, or ameliorating a bone related condition in a mammal, comprising an effective amount of a NELL peptide and a carrier or scaffold that includes BMP2 and hyaluronan, wherein the effective amount is effective for a bone related condition selected from the group consisting of osteoporosis, bone loss due to microgravity, disuse atrophy, prolonged bed-rest, and a disease that involves multiple symptoms where bone metabolism is a secondary effect or is selected from the group consisting of atopic soft tissue calcification, gall stone, kidney stones, pineal gland calcification, cataracts, salivary stones, cardiac valves, and prostate stones. 2. The pharmaceutical composition of claim 1, wherein the NELL peptide is in a dosage not substantially exceeding an optimal dosage range of the NELL peptide. 3. The pharmaceutical composition of claim 1, wherein the NELL peptide is selected from the group consisting of NELL-1, NELL-2, a fragment of NELL-1 peptide, a fragment of NELL-2 peptide, and combinations thereof. 4. The pharmaceutical composition of claim 1, wherein the disease that involves multiple symptoms results in pathological calcification. 5. The pharmaceutical composition of claim 4, wherein the disease that involves multiple symptoms is a chronic kidney disease which causes renal osteodystrophy and/or vascular calcification. 6. The pharmaceutical composition of claim 1, wherein the bone related condition is selected from the group consisting of atopic soft tissue calcification, gall stone, kidney stones, pineal gland calcification, cataracts, salivary stones, cardiac valves, and prostate stones. 7. The pharmaceutical composition of claim 1, further comprising a pharmaceutically acceptable carrier. 8. The pharmaceutical composition of claim 1, further comprising a second agent, wherein the composition is effective for bone generation or treating, preventing, or ameliorating a bone related condition. 9. The pharmaceutical composition of claim 8, wherein the second agent is selected from the group consisting of a BMP protein, a TGFβ protein, FGF, IGF (insulin like growth factors), VEGF, and a combination thereof. 10. The pharmaceutical composition of claim 9, wherein the bone condition is selected from the group consisting of bone fracture, spinal fusion, long bone fracture, craniofacial bone healing or formation, dental or orthopedic implant integration, dental implant integration, or combinations thereof. 11. The pharmaceutical composition of claim 8, further comprising a pharmaceutically acceptable carrier. 12. The pharmaceutical composition of claim 1 in a formulation suitable for a mode of delivery selected from the group consisting of oral delivery, parenteral delivery, pulmonary delivery, and implantation. 13. A scaffold for treating, preventing, or ameliorating a bone related condition in a mammal, comprising an effective amount of a NELL peptide and a carrier that includes BMP2 and hyaluronan, wherein the effective amount is effective for a bone related condition selected from the group consisting of osteoporosis, bone loss due to microgravity, disuse atrophy, prolonged bed-rest, and a disease that involves multiple symptoms where bone metabolism is a secondary effect or is selected from the group consisting of atopic soft tissue calcification, gall stone, kidney stones, pineal gland calcification, cataracts, salivary stones, cardiac valves, and prostate stones. 14. The scaffold of claim 13, wherein the NELL peptide is in a dosage not substantially exceeding an optimal dosage range of the NELL peptide. 15. The scaffold of claim 13, wherein the NELL peptide is selected from the group consisting of NELL-1, NELL-2, a fragment of NELL-1 peptide, a fragment of NELL-2 peptide, and combinations thereof. 16. The scaffold of claim 13, wherein the disease that involves multiple symptoms results in pathological calcification. 17. The scaffold of claim 16, wherein the disease that involves multiple symptoms is a chronic kidney disease which causes renal osteodystrophy and/or vascular calcification. 18. The scaffold of claim 13, wherein the bone related condition is selected from the group consisting of atopic soft tissue calcification, gall stone, kidney stones, pineal gland calcification, cataracts, salivary stones, cardiac valves, and prostate stones. 19. A pharmaceutical composition for treating, preventing, or ameliorating a bone related condition in a mammal, comprising an effective amount of a NELL RNA and a carrier or scaffold that includes BMP2 and hyaluronan, wherein the effective amount is effective for a bone related condition selected from the group consisting of osteoporosis, bone loss due to microgravity, disuse atrophy, prolonged bed-rest, atopic soft tissue calcification, gall stone, kidney stones, pineal gland calcification, cataracts, salivary stones, cardiac valves, prostate stones, and a disease that involves multiple symptoms where bone metabolism is a secondary effect. 20. The pharmaceutical composition of claim 19, wherein the NELL RNA is mRNA, noncoding RNA, microRNA, dsRNA, or combinations thereof. 21. The pharmaceutical composition of claim 19, wherein the NELL RNA is stabilized by a chemical or by incorporating in NELL RNA in a nanocage or biomaterial. 22. A scaffold for treating, preventing, or ameliorating a bone related condition in a mammal, comprising an effective amount of a NELL RNA and a carrier that includes BMP2 and hyaluronan, wherein the effective amount is effective for a bone related condition selected from the group consisting of osteoporosis, bone loss due to microgravity, disuse atrophy, prolonged bed-rest, atopic soft tissue calcification, gall stone, kidney stones, pineal gland calcification, cataracts, salivary stones, cardiac valves, prostate stones, and a disease that involves multiple symptoms where bone metabolism is a secondary effect. 23. The scaffold of claim 22, wherein the NELL RNA is mRNA, noncoding RNA, microRNA, dsRNA, or combinations thereof. 24. The scaffold of claim 22, wherein the NELL RNA is stabilized by a chemical or by incorporating in NELL RNA in a nanocage or biomaterial.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (18)
Jefferies Steven R. (5802 Leith Walk Baltimore MD 21239), Bone graft material for osseous defects and method of making same.
Jefferies Steven R. (5802 Leith Walk Baltimore MD 21239) Gutmann James L. (10112 Daventry Dr. Cockeysville MD 21030) Heatfield Barry M. (33 Penny La. Baltimore MD 21209), Collagen-enzyme conjugates that exhibit no inflammatory response and method for making the same.
Charles Petrie ; Mark V. Craig ; Nand Baindur ; Kirk G. Robbins ; Scott M. Harris ; Maria Kontoyianni ; Gregory R. Mundy, Compositions and methods for treating bone deficit conditions.
Yim Kalvin W. K. (N. andover MA) Huberty Michael C. (Andover MA) Northey ; Jr. Richard P. (Ipswich MA) Schrier Jay A. (Andover MA), Formulations for delivery of osteogenic proteins.
Beertsen Wouter (Santpoort Zuid NLX) van den Bos Theo (Zeist NLX), Implant materials having a phosphatase and an organophosphorus compound for in vivo mineralization of bone.
Peterson Dale R. ; Nousek-Goebl Nancy, Isolation of precursor cells from hematopoietic and nonhematopoietic tissues and their use in vivo bone and cartilage regeneration.
Kuberasampath Thangavel (Medway MA) Cohen Charles M. (Medway MA) Oppermann Hermann (Medway MA) Ozkaynak Engin (Milford MA) Rueger David C. (Hopkinton MA) Pang Roy H. L. (Etna NH), Treatment to prevent loss of and/or increase bone mass in metabolic bone diseases.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.